JP2015523385A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523385A5 JP2015523385A5 JP2015521820A JP2015521820A JP2015523385A5 JP 2015523385 A5 JP2015523385 A5 JP 2015523385A5 JP 2015521820 A JP2015521820 A JP 2015521820A JP 2015521820 A JP2015521820 A JP 2015521820A JP 2015523385 A5 JP2015523385 A5 JP 2015523385A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrocarbyl
- ring
- different
- same
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 148
- 150000001875 compounds Chemical class 0.000 claims 103
- 229910052739 hydrogen Inorganic materials 0.000 claims 86
- 229910052757 nitrogen Inorganic materials 0.000 claims 80
- 125000005842 heteroatom Chemical group 0.000 claims 74
- 239000008194 pharmaceutical composition Substances 0.000 claims 62
- 229910052799 carbon Inorganic materials 0.000 claims 60
- 229910052760 oxygen Inorganic materials 0.000 claims 48
- -1 bisulfate ion Chemical class 0.000 claims 47
- 239000001301 oxygen Substances 0.000 claims 44
- 229910052717 sulfur Inorganic materials 0.000 claims 44
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 42
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 39
- 229910052805 deuterium Inorganic materials 0.000 claims 39
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 38
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 38
- 239000011593 sulfur Substances 0.000 claims 38
- 125000001424 substituent group Chemical group 0.000 claims 32
- 125000003118 aryl group Chemical group 0.000 claims 26
- 229910052736 halogen Inorganic materials 0.000 claims 26
- 150000002367 halogens Chemical class 0.000 claims 26
- 125000004429 atom Chemical group 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 20
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 20
- 125000002950 monocyclic group Chemical group 0.000 claims 14
- RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical group CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 claims 12
- 150000001408 amides Chemical class 0.000 claims 12
- 229940124530 sulfonamide Drugs 0.000 claims 12
- 150000003456 sulfonamides Chemical class 0.000 claims 12
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 150000003857 carboxamides Chemical class 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 10
- 108020001612 μ-opioid receptors Proteins 0.000 claims 9
- 150000001450 anions Chemical class 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 6
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 229920006395 saturated elastomer Polymers 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 102000013366 Filamin Human genes 0.000 claims 4
- 108060002900 Filamin Proteins 0.000 claims 4
- 125000001931 aliphatic group Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 4
- 229960004127 naloxone Drugs 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000006413 ring segment Chemical group 0.000 claims 4
- 230000000638 stimulation Effects 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- 108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 claims 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 229940077388 benzenesulfonate Drugs 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 229940085991 phosphate ion Drugs 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 102000051367 mu Opioid Receptors Human genes 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 102000013498 tau Proteins Human genes 0.000 claims 1
- 108010026424 tau Proteins Proteins 0.000 claims 1
- 0 *C(BN(*)*)*OC(C1)[C@]2C1[C@@](CC1)C1CC2 Chemical compound *C(BN(*)*)*OC(C1)[C@]2C1[C@@](CC1)C1CC2 0.000 description 5
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261671235P | 2012-07-13 | 2012-07-13 | |
| US61/671,235 | 2012-07-13 | ||
| US201361789180P | 2013-03-15 | 2013-03-15 | |
| US61/789,180 | 2013-03-15 | ||
| PCT/US2013/050126 WO2014011917A2 (en) | 2012-07-13 | 2013-07-11 | A method of inhibiting tau phosphorylation |
| US13/940,016 | 2013-07-11 | ||
| US13/940,016 US10017736B2 (en) | 2012-07-13 | 2013-07-11 | Method of inhibiting tau phosphorylation |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018000198A Division JP6630374B2 (ja) | 2012-07-13 | 2018-01-04 | τリン酸化を阻害する方法 |
| JP2018189789A Division JP2019031520A (ja) | 2012-07-13 | 2018-10-05 | τリン酸化を阻害する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015523385A JP2015523385A (ja) | 2015-08-13 |
| JP2015523385A5 true JP2015523385A5 (OSRAM) | 2016-09-01 |
| JP6417324B2 JP6417324B2 (ja) | 2018-11-07 |
Family
ID=49914489
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521820A Active JP6417324B2 (ja) | 2012-07-13 | 2013-07-11 | τリン酸化を阻害する方法 |
| JP2018000198A Active JP6630374B2 (ja) | 2012-07-13 | 2018-01-04 | τリン酸化を阻害する方法 |
| JP2018189789A Pending JP2019031520A (ja) | 2012-07-13 | 2018-10-05 | τリン酸化を阻害する方法 |
| JP2021089538A Pending JP2022000421A (ja) | 2012-07-13 | 2021-05-27 | τリン酸化を阻害する方法 |
| JP2022198455A Active JP7419486B2 (ja) | 2012-07-13 | 2022-12-13 | τリン酸化を阻害する方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018000198A Active JP6630374B2 (ja) | 2012-07-13 | 2018-01-04 | τリン酸化を阻害する方法 |
| JP2018189789A Pending JP2019031520A (ja) | 2012-07-13 | 2018-10-05 | τリン酸化を阻害する方法 |
| JP2021089538A Pending JP2022000421A (ja) | 2012-07-13 | 2021-05-27 | τリン酸化を阻害する方法 |
| JP2022198455A Active JP7419486B2 (ja) | 2012-07-13 | 2022-12-13 | τリン酸化を阻害する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US10017736B2 (OSRAM) |
| EP (1) | EP2882428B1 (OSRAM) |
| JP (5) | JP6417324B2 (OSRAM) |
| DK (1) | DK2882428T3 (OSRAM) |
| ES (1) | ES2716049T3 (OSRAM) |
| WO (1) | WO2014011917A2 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2872899B1 (en) * | 2012-07-13 | 2018-07-11 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patient |
| GB201312499D0 (en) * | 2013-07-12 | 2013-08-28 | Isis Innovation | Therapeutic compounds |
| US9433604B2 (en) | 2013-10-08 | 2016-09-06 | Pain Therapeutics Inc. | Method for inhibiting growth of cancer cells |
| CN104030933A (zh) * | 2014-05-16 | 2014-09-10 | 烟台恒迪克能源科技有限公司 | 一种β-异烷醇基氨基戊酸环己胺的合成方法 |
| MA44037B1 (fr) | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| US11040935B2 (en) | 2016-10-05 | 2021-06-22 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule AMPK activators |
| US12186307B2 (en) | 2019-02-13 | 2025-01-07 | Yale University | Methods of treating epilepsy |
| AU2020224678B2 (en) * | 2019-02-21 | 2024-03-14 | Pain Therapeutics, Inc. | Solid polymorphs of a FLNA-binding compound and its hydrochloride salts |
| WO2021050538A1 (en) | 2019-09-10 | 2021-03-18 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods and materials for increasing level of phosphorylated ampk protein |
| WO2021145372A1 (ja) * | 2020-01-15 | 2021-07-22 | 国立大学法人東海国立大学機構 | 進行性核上性麻痺の治療 |
| US20220233512A1 (en) * | 2020-11-03 | 2022-07-28 | Cassava Sciences, Inc. | Inhibiting an immune response mediated by one or more of tlr2, rage, ccr5, cxcr4 and cd4 |
| CN114252324B (zh) * | 2022-03-02 | 2022-05-13 | 中国人民解放军军事科学院军事医学研究院 | 一种方便使用的多孔脑片孵育装置 |
| WO2024151661A2 (en) * | 2023-01-10 | 2024-07-18 | Washington University | Methods of decreasing pathological neuroinflammation |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3723442A (en) | 1970-12-31 | 1973-03-27 | Yoshitomi Pharmaceutical | 3-oxo-1-oxa-4,8-diazaspiro(4.5)decanes |
| US4981858A (en) | 1987-08-13 | 1991-01-01 | State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research | Optical isomers |
| ES2074441T3 (es) | 1987-10-05 | 1995-09-16 | Yamanouchi Pharma Co Ltd | Compuestos espiro heterociclicos y su preparacion. |
| US5534520A (en) | 1990-04-10 | 1996-07-09 | Fisher; Abraham | Spiro compounds containing five-membered rings |
| US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| AU693087B2 (en) | 1993-01-28 | 1998-06-25 | Merck & Co., Inc. | Spiro-substituted azacycles as tachykinin receptor antagonists |
| JP2000500760A (ja) | 1995-11-23 | 2000-01-25 | メルク シヤープ エンド ドーム リミテツド | スピロピペリジン誘導体およびタキキニン拮抗薬としてのその使用 |
| PT1083889E (pt) * | 1998-06-01 | 2004-04-30 | Ortho Mcneil Pharm Inc | Compostos de tetra-hidronaftaleno e sua utilizacao no tratamento de doencas neurodegenerativas |
| DE10130020A1 (de) | 2001-06-25 | 2003-12-04 | Gruenenthal Gmbh | Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate |
| ATE396995T1 (de) | 2001-07-23 | 2008-06-15 | Banyu Pharma Co Ltd | 4-oxoimidazolidin-2-spiro piperidin derivat |
| EP1507765A4 (en) | 2002-05-03 | 2006-11-02 | Israel Inst Biolog Res | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND RELATED COMPOUNDS |
| DE102004014304A1 (de) | 2004-03-22 | 2005-10-06 | Grünenthal GmbH | Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen |
| DE102004014296A1 (de) | 2004-03-22 | 2005-10-06 | Grünenthal GmbH | Substituierte 1,4,8-Triazaspiro[4.5]decan-2-on-Verbindingen |
| AU2005244852B2 (en) * | 2004-05-12 | 2011-09-22 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods related to the treatment of neurodegenerative and inflammatory conditions |
| DE102005030051A1 (de) | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| AR057579A1 (es) | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
| WO2009059225A2 (en) * | 2007-11-02 | 2009-05-07 | Pain Therapeutics, Inc. | Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin a |
| US20100280057A1 (en) * | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Novel analgesic that binds filamin a |
| US8614324B2 (en) | 2008-10-31 | 2013-12-24 | Pain Therapeutics, Inc. | Filamin A binding anti-inflammatory and analgesic |
| US8653068B2 (en) | 2009-10-30 | 2014-02-18 | Pain Therapeutics, Inc. | Filamin A binding anti-inflammatory and analgesic |
| EP2488177B1 (en) * | 2008-10-31 | 2016-10-12 | Pain Therapeutics, Inc. | Filamin a binding anti-inflammatory and analgesic |
| US8580808B2 (en) | 2009-10-30 | 2013-11-12 | Pain Therapeutic, Inc. | Filamin A-binding anti-inflammatory analgesic |
| US20100279996A1 (en) | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Novel analgesic that binds filamin a |
| US20100279997A1 (en) * | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Analgesic that binds filamin a |
| JP5874878B2 (ja) | 2009-01-26 | 2016-03-02 | イスラエル インスティトゥート フォー バイオロジカル リサーチ | 複素二環スピロ化合物又はその薬学的に許容される塩、これらの化合物を含む医薬組成物、および哺乳類のアルツハイマー病及びインスリン抵抗性症候群及び２型糖尿病を治療するための薬剤の調整における、これらの化合物の利用 |
| US20100280061A1 (en) | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Novel analgesic that binds filamin a |
| TWI374662B (en) * | 2009-05-18 | 2012-10-11 | Novatek Microelectronics Corp | Image processing circuit and method thereof |
| US8580809B2 (en) | 2009-10-30 | 2013-11-12 | Pain Therapeutics, Inc. | Filamin A-binding anti-inflammatory analgesic |
| US20140094482A1 (en) * | 2012-08-16 | 2014-04-03 | George B. Thornton | Benzazocine-ring compound inhibition of tau hyperphosphorylation |
-
2013
- 2013-07-11 DK DK13816713.5T patent/DK2882428T3/en active
- 2013-07-11 EP EP13816713.5A patent/EP2882428B1/en active Active
- 2013-07-11 WO PCT/US2013/050126 patent/WO2014011917A2/en not_active Ceased
- 2013-07-11 US US13/940,016 patent/US10017736B2/en active Active
- 2013-07-11 JP JP2015521820A patent/JP6417324B2/ja active Active
- 2013-07-11 ES ES13816713T patent/ES2716049T3/es active Active
-
2018
- 2018-01-04 JP JP2018000198A patent/JP6630374B2/ja active Active
- 2018-07-09 US US16/030,494 patent/US10760052B2/en active Active
- 2018-10-05 JP JP2018189789A patent/JP2019031520A/ja active Pending
-
2020
- 2020-08-28 US US17/006,338 patent/US11661580B2/en active Active
-
2021
- 2021-05-27 JP JP2021089538A patent/JP2022000421A/ja active Pending
- 2021-08-20 US US17/408,038 patent/US20210389298A1/en not_active Abandoned
-
2022
- 2022-12-13 JP JP2022198455A patent/JP7419486B2/ja active Active
-
2023
- 2023-05-24 US US18/323,075 patent/US20240117306A1/en not_active Abandoned
-
2024
- 2024-11-21 US US18/955,938 patent/US20250163372A1/en active Pending
- 2024-11-21 US US18/955,937 patent/US20250092361A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015523385A5 (OSRAM) | ||
| JP2022000421A5 (OSRAM) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP6629947B2 (ja) | 高インスリン血症に関連した症状の処置 | |
| AU2019264253B2 (en) | Factor XIIa inhibitors | |
| JP2023036695A5 (OSRAM) | ||
| JP2015529802A5 (OSRAM) | ||
| JP2016512531A5 (OSRAM) | ||
| ZA200403685B (en) | Cannabinoid receptor ligands. | |
| BR112015004205B1 (pt) | Sulfamoil-arilamidas, seu uso das mesmas como medicamentos para o tratamento da hepatite b, composição farmacêutica que as compreende e produto | |
| JP2016518430A5 (OSRAM) | ||
| CA2800998A1 (en) | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities | |
| CA2654315A1 (en) | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridines and their use | |
| EP3191472A1 (en) | Compounds and compositions as raf kinase inhibitors | |
| BRPI0611099A2 (pt) | polimorfos de éster etìlico de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamin o]-metil}-1- metil-1h-benzimidazol-5-carbonil)-piridin-2-il-amino]-p ropiÈnico, composição farmacêutica, processo de preparação dos ditos compostos e o uso dos mesmos | |
| JP2021501756A5 (OSRAM) | ||
| HUT77735A (hu) | Triazinszármazékok és ezeket tartalmazó gyógyászati készítmények | |
| IL296653A (en) | A process for producing profortin inhibitors | |
| RU2016106125A (ru) | Соли дасатиниба в кристаллической форме | |
| JP2015502371A5 (OSRAM) | ||
| TW201813965A (zh) | 結晶型式 | |
| RU2014133518A (ru) | Производные пиперазинил пиримидина, способ их получения и их применение | |
| AU2017341020A2 (en) | Urea derivative | |
| JP2010513455A (ja) | Ｔｒｐｖ１受容体拮抗薬としてのｏ−置換ジベンジル尿素誘導体 | |
| CN111801325A (zh) | 作为Wnt信号转导通路的抑制剂的吡唑衍生物 |